Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Development of Protease-activated Receptor-2 (PAR-2) Antagonist for Chronic Dermatitis Improving Agent_NEOPHARM Co.,Ltd.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Development of protease-activated receptor-2 (PAR-2) antagonist for chronic dermatitis improving agent...
Contact Yong U Kim
Participants
You
Email me a copy of this message

The core technology of NeoPharm is the method to manufacture the composite for treating the flammable disease using the novel PAR-2 inhibiter material, the heterocyclic compound.


Background and unmet needs


It is expected that the PAR-2 inhibiter will be effective for the flammable response of skin, pruritus, pigmentation, cut healing, and so on. However, a commercialized inhibiter is not developed.


NPS-1577, the PAR-2 inhibiter developed through the technical development, is the first commercialized PAR-2 inhibiter in the world. In order to make it possible to be used as the natural material of cosmetics, the toxicity, safety, and in-vitro toxicity tests corresponding to the KFDA standards of the raw materials of cosmetics were done. The safety was checked through the patch test and the clinical test on the final product.


Moreover, it was registered in the ICID (International Cosmetic Ingredient Dictionary).


Discovery and Achievements


It had the effects of alleviating the dermatitis in the model of an animal with acute dermatitis and alleviating the inflammation, improving the function of the skin wall, and inhibiting the skin permeation of an inflammable cell in the model of an animal with chronic dermatitis.


As the result of the clinical test on the atopic dermatitis of the product containing 0.1% NPS-1577, the atopic dermatitis symptom (SCORAD index), the itchiness symptom, and the comprehensive clinical evaluation were improved.


Toxicological data


The toxicity and safety test results showed that it is safe in all the items of the single administration cavity toxicity, skin stimulation, phototoxicity, photosensitization, skin sensitization tests. The in-vitro toxicity test results showed that it is the comparatively safe compound in all the in-vitro metabolic stability, CYP450 screening, cell toxicity, hERG K+ channel, and hERG binding tests.


According to the patch test done by a dermatologist on the final product, the skin stimulation was not observed. According to the clinical test on the atopic dermatitis patients and the psoriasis patients, the side effects including the skin stimulation were not observed. Hence, it is thought to be a safe material.


 

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE